Pulmatrix Business Summary

Pulmatrix, Inc. (PULM) is a clinical-stage biopharmaceutical company that historically generated revenue through strategic licensing and R&D partnerships, though it currently operates with negligible revenue ($3K TTM) as it executes a strategic divestment of its core assets. The company’s business model is centered on its proprietary iSPERSE™ (Inhaled Small Particles Easily Respirable and Emittable) technology, which facilitates the delivery of small molecules and biologics via dry powder inhalation. Its primary business segments are defined by its clinical pipeline, including PUR3100 for acute migraine, PUR1800 for chronic obstructive pulmonary disease (COPD), and PUR1900, an antifungal partnered with Cipla. As of February 2026, Pulmatrix is in a transitional phase, pursuing a reverse merger with Cullgen Inc. while simultaneously exploring alternative transactions following a mutual waiver of non-solicitation clauses in late 2025. Direct competitors include Verona Pharma, Enterprise Therapeutics, and Windtree Therapeutics; Pulmatrix occupies a micro-cap, distressed-market position, focusing on asset liquidation or merger completion to sustain its remaining operations. Pulmatrix was founded in 2003 by a distinguished team of materials science experts from MIT and Harvard, including Robert Langer, Alexander Klibanov, and David Edwards. Current leadership is headed by Peter Ludlum, who serves as Interim CEO and Interim CFO, bringing over 23 years of life sciences financial experience from Danforth Advisors and various pharmaceutical leadership roles. The executive team is supported by Vice President of Quality Steven Kramer, a long-tenured leader with the firm since 2009. Pulmatrix’s Board of Directors features high-pedigree industry veterans, including Independent Chairman Michael J. Higgins (formerly of Ironwood Pharmaceuticals and Genzyme) and Steven Gillis, a Managing Director at ARCH Venture Partners and co-founder of Immunex. Notable institutional backing includes ARCH Venture Partners and Polaris Partners, alongside significant holdings from SBI Securities and Vanguard.